ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0830

Smartphone Assisted Patient Initiated Care Safely Reduces Outpatient Clinic Visits in Patients with Rheumatoid Arthritis: Results from a Randomized Controlled Trial

Bart Seppen1, Jimmy Wiegel1, Marieke ter wee2, DirkJan van Schaardenburg1, Leo Roorda1, Michael Nurmohamed3 and wouter Bos4, 1Reade, Amsterdam, Netherlands, 2Amsterdam UMC, location VUmc, Amsterdam, Netherlands, 3Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, 4Reade Amsterdam, Amsterdam, Netherlands

Meeting: ACR Convergence 2021

Keywords: Access to care, Patient reported outcomes, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: The demand on outpatient rheumatology clinics is high due to protocolised visits of rheumatoid arthritis (RA) patients, including those in low disease activity or remission. We developed a mobile phone app for patients with RA, which allows them to self-monitor their disease activity in between clinic visits by answering a weekly routine assessment of patient index data (RAPID-3). The objective of this study is to assess efficacy and safety of self-initiated care assisted by a smartphone app in patients with RA.

Methods: A randomised controlled trial was performed with a study duration of one year. Inclusion criteria were: 1) diagnosed with RA by a rheumatologist, 2) disease duration of at least two years and 3) a Disease Activity Score 28 (DAS28) below 3.2 at the start of the study. Patients were excluded if they had initiated or discontinued conventional DMARDs or a biological in the previous 6 months. Patients were randomised to either app supported self-initiated care with only one scheduled follow-up consultation after a year (app-group) or to usual care. The app warned patients that they could be flaring when RAPID-3 scores increased more than 2 points and the overall score was over 4. The co-primary outcome was mean number of consultations with a rheumatologist and non-inferiority in terms of difference in DAS28 at 12 months. The non-inferiority limit was set at 0.5 difference in DAS28 between the groups. Secondary outcomes included consultations with nurses, satisfaction with healthcare and app usage.

Results: In total, 103 patients were randomised to usual care (n=53) or to the app group (n=50). Baseline characteristics were similar in both groups (table 1). At 12 months, the mean number (±SD) of outpatient or telephone consultations with the rheumatologist was significantly lower in the app group compared with usual care (1.7±1.8 vs 3.0±1.4, p< 0.001). The same applied to the nurse outpatient or telephone consultations (0.4±1.0 vs 0.9±1.1, p=0.03; table 2). Non-inferiority was established as the 95% confidence interval of the mean difference in DAS28 between the groups was within the non-inferiority limit: -0.04 in favour of the intervention group ([95% CI], -0,39, 0.30). Satisfaction with healthcare received was high (8.6 out of 10 ±1.3) in both groups and not statistically different. On average patients completed 56% (29/52, SD13.3) of the weekly questionnaires.

Conclusion: The results of this study show that self-initiated care supported with weekly RAPID3 self-monitoring via a smartphone app reduces the number of outpatient visits and telephone consultations and is non-inferior to usual care in terms of the DAS28. We propose the implementation of this approach to optimise rheumatologic care for RA patients in low disease activity.

Table 1. Baseline characteristics. Data are mean (SD) or percentage.

Table 2. Number of consultations per group. Means and standard deviation (SD) are presented. CI: 95% Confidence Interval.


Disclosures: B. Seppen, None; J. Wiegel, None; M. ter wee, None; D. van Schaardenburg, None; L. Roorda, None; M. Nurmohamed, Pfizer, 2, 5, 6, AbbVie, 2, 5, 6, Roche, 2, 5, 6, Bristol-Myers Squibb, 2, 5, 6, MSD, 2, 5, 6, Mundipharma, 2, 5, 6, UCB, 2, 5, 6, Janssen, 2, 5, 6, Menarini, 2, 5, 6, Lilly, 2, 5, 6, Celgene, 2, 5, 6, Sanofi, 2, 5, 6, Gilead/Galapagos, 2, 5; w. Bos, Abbvie, 5, Pfizer, 5, Novartis, 5.

To cite this abstract in AMA style:

Seppen B, Wiegel J, ter wee M, van Schaardenburg D, Roorda L, Nurmohamed M, Bos w. Smartphone Assisted Patient Initiated Care Safely Reduces Outpatient Clinic Visits in Patients with Rheumatoid Arthritis: Results from a Randomized Controlled Trial [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/smartphone-assisted-patient-initiated-care-safely-reduces-outpatient-clinic-visits-in-patients-with-rheumatoid-arthritis-results-from-a-randomized-controlled-trial/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/smartphone-assisted-patient-initiated-care-safely-reduces-outpatient-clinic-visits-in-patients-with-rheumatoid-arthritis-results-from-a-randomized-controlled-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology